FY2025 · period end Dec '25 · from the 10-K filed Feb 25, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0.13B | $0.14B | $0.09B | $0.05B | $0.02B |
| Gross Profit | $0.10B | $0.10B | $0.05B | $0.02B | $0.00B |
| Operating Income | negative: -$0.05B | negative: -$0.04B | negative: -$0.05B | negative: -$0.06B | negative: -$0.05B |
| Net Income | negative: -$0.00B | negative: -$0.00B | negative: -$0.00B | negative: -$0.00B | negative: -$0.05B |
| EPS (Diluted) | negative: -$0.95 | negative: -$0.71 | negative: -$1.41 | negative: -$2.41 | negative: -$3.57 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $0.31B | $0.32B | $0.18B | $0.15B | $0.19B |
| Total Liabilities | $0.04B | $0.04B | $0.02B | $0.06B | $0.05B |
| Stockholders' Equity | $0.28B | $0.28B | $0.16B | $0.09B | $0.14B |
| Cash & Equivalents | $0.02B | $0.02B | $0.01B | $0.01B | $0.02B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | negative: -$0.02B | negative: -$0.02B | negative: -$0.04B | negative: -$0.06B | negative: -$0.04B |
| Capital Expenditures | $0.00B | $0.01B | $0.00B | $0.00B | $0.00B |
| Free Cash Flow | negative: -$0.02B | negative: -$0.02B | negative: -$0.05B | negative: -$0.06B | negative: -$0.05B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 76.6% | 70.7% | 60.4% | 43.5% | 20.0% |
| Operating Margin | negative: -0.4% | negative: -0.3% | negative: -0.6% | negative: -1.3% | negative: -2.3% |
| Net Margin | negative: -0.0% | negative: -0.0% | negative: -0.0% | negative: -0.0% | negative: -2.2% |
| Return on Equity | negative: -0.0% | negative: -0.0% | negative: -0.0% | negative: -0.0% | negative: -35.2% |
| Return on Assets | negative: -0.0% | negative: -0.0% | negative: -0.0% | negative: -0.0% | negative: -33.2% |
| Debt / Equity | — | — | — | — | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001193125-26-335150 | Aug 5, 2026 | Aug 5, 2026 | Aug 5, 2026 20:15 UTC | EDGAR |
| 10-Q | 0001193125-26-335153 | Jun 30, 2026 | Aug 5, 2026 | Aug 5, 2026 20:15 UTC | EDGAR |
| 8-K | 0001193125-26-304812 | Jul 13, 2026 | Jul 15, 2026 | Jul 15, 2026 20:23 UTC | EDGAR |
| 8-K | 0001193125-26-296200 | Jul 6, 2026 | Jul 6, 2026 | Jul 6, 2026 20:15 UTC | EDGAR |
| 8-K | 0001193125-26-296201 | Jun 30, 2026 | Jul 6, 2026 | Jul 6, 2026 20:15 UTC | EDGAR |
| 8-K | 0001193125-26-272688 | Jun 16, 2026 | Jun 16, 2026 | Jun 16, 2026 20:30 UTC | EDGAR |
| 8-K | 0001193125-26-208912 | May 6, 2026 | May 6, 2026 | May 6, 2026 20:04 UTC | EDGAR |
| 10-Q | 0001193125-26-208921 | Mar 31, 2026 | May 6, 2026 | May 6, 2026 20:05 UTC | EDGAR |
Direct links to SEC EDGAR. RXST has additional filings available on the SEC site.
6 numbers RxSight, Inc. later changed — same XBRL tag, both filings linked.
Net Income (Loss) Attributable to Parent·FY 2025
Major restatementwas-$38.9M
Revised up.
Net Income (Loss) Attributable to Parent·FY 2023
Major restatementwas-$48.6M
Revised up.
Net Income (Loss) Attributable to Parent·FY 2022
Major restatementwas-$66.8M
Revised up.
Net Income (Loss) Attributable to Parent·FY 2024
Major restatementwas-$27.5M
Revised up.
Operating Expenses·Q2 2025
Major restatementwas$39.2M
Revised up in a 10-Q.
Other Accrued Liabilities, Current·As of Dec 31, 2021
Major restatementwas$135K
Revised up in a 10-K.
RXST is not the only one.
See every restatement we've found across the market — or get an alert the next time RXST revises a number.
Restatements are detected by comparing every vintage of a fact across all of RxSight, Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows RXST's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling RxSight, Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on RXST yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on RXST and publish the result to your public profile.
Ask about RxSight, Inc.
Continue in Workspace — cited answers on RXST, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs